All In Biotech

Drug Trial Radar · NCT00433511

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,994 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

4,994

Actual

Start

Nov 2, 2007

Primary completion

Jan 7, 2014

Study completion Feb 20, 2027

Sponsor

Sponsor type
NIH
First posted
Feb 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, and paclitaxel to see how well they work with or without bevacizumab in treating patients with cancer that has spread to the lymph nodes (lymph node-positive) or cancer that has not spread to the lymph nodes but is at high risk for returning (high-risk, lymph node-negative breast cancer). Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery and help prevent the tumor from returning. It is not yet known whether doxorubicin hydrochloride, cyclophosphamide, and paclitaxel are more effective with or without bevacizumab.

Conditions

  • Breast Adenocarcinoma

Interventions

  • BevacizumabBiological

    Given IV

  • CyclophosphamideDrug

    Given IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PaclitaxelDrug

    Given IV

  • Placebo AdministrationOther

    Given IV

  • Quality-of-Life AssessmentOther

    Ancillary studies (closed as of 5/28/10)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-free Survival (IDFS) Rate at 5 YearsTime frame: Assessed at 5 years

Locations

842 sites in 3 countries. Site status is shown where the registry gives one.

  • Northeast Alabama Regional Medical Center

    Anniston, Alabama

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Providence Hospital

    Mobile, Alabama

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Virginia G Piper Cancer Care-Del Camino

    Scottsdale, Arizona

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • PCR Oncology

    Arroyo Grande, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Valley Medical Oncology Consultants-Castro Valley

    Castro Valley, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Valley Medical Oncology Consultants-Fremont

    Fremont, California

  • Washington Health

    Fremont, California

  • California Cancer Associates for Research and Excellence (cCare)

    Fresno, California

  • Glendale Memorial Hospital and Health Center

    Glendale, California

  • Marin Cancer Care Inc

    Greenbrae, California

  • Marin General Hospital

    Greenbrae, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Community Hospital of Monterey Peninsula

    Monterey, California

  • El Camino Hospital

    Mountain View, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Wilma Chan Highland Hospital

    Oakland, California

  • Alta Bates Summit Medical Center - Summit Campus

    Oakland, California

  • Bay Area Tumor Institute

    Oakland, California

  • Hematology and Oncology Associates-Oakland

    Oakland, California

  • Tom K Lee Inc

    Oakland, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Desert Regional Medical Center

    Palm Springs, California

Showing 40 of 842 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.